Team:Freiburg/Content/Team/Members

From 2014.igem.org

(Difference between revisions)
Line 34: Line 34:
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
<figcaption>
<figcaption>
-
<p class="header">Team</p>
+
<p class="header">OH Le Ole</p>
</figcaption>
</figcaption>
</figure>
</figure>
Line 46: Line 46:
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
<figcaption>
<figcaption>
-
<p class="header">Team</p>
+
<p class="header">Chrys</p>
</figcaption>
</figcaption>
-
      </figure>
+
      </figure>
</div>
</div>
<div class="col-sm-6">
<div class="col-sm-6">
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Ileana-Bender">Ileana Bender</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Illi-Vanilli</p>
 +
</figcaption>
 +
</figure>
</div>
</div>
</div>
</div>
 +
<h2 id="Team-Valentina-Diehl">Valentina Diehl</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Vali</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
<h2 id="Team-Mirja-Harms">Mirja Harms</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">MirNEIN</p>
 +
</figcaption>
 +
</figure>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Patrick-Heisterkamp">Patrick Heisterkamp</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Appologe</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Clarissa-Hiltl">Clarissa Hiltl</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">CEO von HZ Corp.</p>
 +
</figcaption>
 +
</figure>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Jiangliang-Lu">Jiangliang Lu</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">LaLeLu</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Wignand-Mühlhäuser">Wignand Mühlhäuser</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Weegee</p>
 +
</figcaption>
 +
</figure>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Marc-Müller">Marc Müller</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Hexer</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Laura-Ost">Laura Ost</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Sonnenaufgang</p>
 +
</figcaption>
 +
</figure>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Pascal-Sartor">Pascal Sartor</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Dizzie Pascal</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Kristoffer-Weißert">Kristoffer Weißert</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Krissi</p>
 +
</figcaption>
 +
</figure>
 +
</div>
 +
</div>
 +
 +
<h2 id="Team-Dennis-Zimmer">Dennis Zimmer</h2>
 +
<div class="row category-row">
 +
<div class="col-sm-6">
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2014/6/63/2014Freiburg_Viral_specificity_schema.jpg">
 +
<figcaption>
 +
<p class="header">Chambre</p>
 +
</figcaption>
 +
      </figure>
 +
</div>
 +
<div class="col-sm-6">
 +
<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 +
</div>
 +
</div>
 +
</section>
</section>

Revision as of 17:53, 9 October 2014

The AcCELLerator

Team

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Team

Members

Jan Ole Ackermann

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

OH Le Ole

Christoph Bauer

Chrys

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Ileana Bender

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Illi-Vanilli

Valentina Diehl

Vali

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Mirja Harms

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

MirNEIN

Patrick Heisterkamp

Appologe

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Clarissa Hiltl

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

CEO von HZ Corp.

Jiangliang Lu

LaLeLu

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Wignand Mühlhäuser

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Weegee

Marc Müller

Hexer

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Laura Ost

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Sonnenaufgang

Pascal Sartor

Dizzie Pascal

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Kristoffer Weißert

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Krissi

Dennis Zimmer

Chambre

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Retrieved from "http://2014.igem.org/Team:Freiburg/Content/Team/Members"